Noninvasive Management of Rhesus Alloimmunization

Nirmala Agarwal, Sweta Balani, Subhash Arya, Ratna Dua Puri

ABSTRACT

Rhesus alloimmunization causes fetal hemolysis, anemia and hydrops leading to stillbirth, neonatal morbidity or mortality. We describe successful management of two cases of Rhesus alloimmunization with high anti-D titers, by the ultrasound Doppler measurement of their peak systolic velocity in the middle cerebral artery (PSV-MCA) and multiple maternal administrations of intravenous immunoglobulin (IVIg).

Keywords: Rhesus alloimmunization, Intravenous immunoglobulin, Middle cerebral artery peak systolic velocity.

INTRODUCTION

Maternal rhesus alloimmunization occurs when a rhesus-negative pregnant women develops antibody response to fetal red cell rhesus antigen. These antibodies cross placenta and destroy fetal erythrocytes leading to anemia, hydrops and fetal death. It has been estimated that 35 fetuses out of every 10,000 live births are at a risk of anemia because of maternal rhesus alloimmunization.1 Traditionally, such pregnant women were managed by carrying out an amniocentesis, cordocentesis and intrauterine transfusion. Only 10% of their fetus have severe anemia and require cordocentesis before 34 weeks.2 Although cordocentesis allows direct measurement of fetal hemoglobin, it is associated with infection, bleeding, fetal bradycardia, premature rupture of the membranes including a procedure-related pregnancy loss of 1%.3 Even though amniocentesis is less invasive than cordocentesis, it is reliable only after 27 weeks.4 Currently, it is possible to offer an accurate prediction of severity of anemia using ultrasound by measuring peak systolic velocity in the middle cerebral artery (PSV-MCA).5 There is a reverse relationship between the fetal hemoglobin concentration and velocity of the cerebral blood flow. To evaluate PSV-MCA, nomograms are made for various gestational age.6 Recent studies administering maternal intravenous immunoglobulin (IVIg) have shown some benefit in severe cases.7 Studies have been carried out using plasmapheresis with IVIg. The recommended dose has been of 1 gm/kg which is repeated weekly.8

We describe two cases of rhesus alloimmunization that were successfully managed at a private tertiary care hospital by noninvasive technique.

CASE REPORTS

Case 1

This patient was 39 years old G5 P4 L1 NND2 SB1 with IVF singleton RH negative 19 weeks pregnancy. Her first pregnancy was uneventful and she had delivered a female baby 19 years earlier. Anti-D was not given in postnatal period. Following this, second and third pregnancy resulted in neonatal death on day 1 due to severe anemia. The fourth pregnancy also ended in a stillbirth at term. In present pregnancy, her antibody titer was 1:256.

The pregnancy was monitored with MCA-PCV according to normogram.5 She was given 5 gm of IVIg (IV Nex, Biocon) starting at 19 weeks, IVIg was repeated every 2 weeks. She was followed according to the PSV-MCA value (Table 1). The dose of IVIg was increased to 10 gm. Patient declined to receive any IVIg after 26 weeks (financial reason). At 33 weeks, fetal PSV-MCA value showed sudden increase and was plotted in zone b (Graph 1). Repeat Doppler 5 days later, there was further increase in MCA-PSV above 1.5 MoM. Emergency cesarean section was done at 34 + 6 weeks of pregnancy; a female baby of 2.6 kg was delivered. Baby’s hemoglobin was 5 gm%, with tear drop cell and fragmented RBC. Exchange transfusion was given twice. Newborn was discharged on 8th postnatal day.

Case 2

This patient was 38 years old G5 P4 L1 NND2 SB1 with IVF singleton RH negative 19 weeks pregnancy. Her first pregnancy was uneventful and she had delivered a female baby 19 years earlier. Anti-D was not given in postnatal period. Following this, second and third pregnancy resulted in neonatal death on day 1 due to severe anemia. The fourth pregnancy also ended in a stillbirth at term. In present pregnancy, her antibody titer was 1:256.

The pregnancy was monitored with MCA-PCV according to normogram.5 She was given 5 gm of IVIg (IV Nex, Biocon) starting at 19 weeks, IVIg was repeated every 2 weeks. She was followed according to the PSV-MCA value (Table 1). The dose of IVIg was increased to 10 gm. Patient declined to receive any IVIg after 26 weeks (financial reason). At 33 weeks, fetal PSV-MCA value showed sudden increase and was plotted in zone b (Graph 1). Repeat Doppler 5 days later, there was further increase in MCA-PSV above 1.5 MoM. Emergency cesarean section was done at 34 + 6 weeks of pregnancy; a female baby of 2.6 kg was delivered. Baby’s hemoglobin was 5 gm%, with tear drop cell and fragmented RBC. Exchange transfusion was given twice. Newborn was discharged on 8th postnatal day.
The present pregnancy was spontaneous singleton pregnancy. Her husband was O positive (homogyous). In this pregnancy, her ICT titer was 1:32. She was given 5 gm of immunoglobulin from 12 week onward and this was repeated every fortnightly. From 18 weeks onward, she was monitored by ultrasound Doppler MCA-PSV (Table 2). At 24 weeks, the PSV-MCA reached zone C of (Mari et al) normogram (Graph 1). IVIg dose was increased to 10 gm fortnightly. In spite of all these measures, the PSV-MCA went into zone B. The dose of IVIg was further increased to 15 gm every 2 weekly. The aim was to avoid PSV-MCA value to reach zone A where transfusion would have been recommended. Finally at 34 weeks, she was given steroid cover for lung maturation (betamethasone 12 mg, two doses at 24 hours interval) and cesarean section was done at 34 weeks. She delivered 2.2 kg female infant. Baby’s hemoglobin was 14 gm% with a normal peripheral picture and did not require any exchange transfusion and discharged on 3rd day.

**DISCUSSION**

The sensitivity of increased PSV-MCA for prediction of moderate to severe anemia was cent percent either in the presence or absence of hydrops with false-positive rate of 12%. To the best of our knowledge, the literature on use of IVIg in Rh isoimmunization is scant. Though, anecdotal reports suggest that noninvasive therapy with IVIg may be extremely useful in management of severe Rh isoimmunization. The only concern is the cost of such a therapy which was evident the above case one who had declined IVIg after 26 weeks and was monitored by MCA-PSV. The recommended dose is 1 gm/kg every week but, in both our cases, we have used lower dose with good outcome. IVIg should not be expected to eliminate the need for intravascular transfusion but can prolong the interval before the first transfusion is necessary. The mechanism of IVIg is not completely known. In all probability, it downregulates maternal antibody response, prevents transport of antibodies across placenta and block destruction of fetal cell by occupying the Fc receptor site. The typical side effects are urticaria and severe headache. We encountered no side effect in these two patients. Further research input is warranted to decide the ideal IVIg schedule doses and safety profile, since high dose IVIg is used in neonates to reduce exchange transfusion with hemolytic disease due to rhesus and/or ABO compatibility. This has been and is effective in reducing the duration of phototherapy in the neonates including hospital stay.10

The hemoglobin value in the above two neonates were 5 and 14 gm% respectively. The lower hemoglobin value was most likely due to inadequate dosage of IVIg which had to be discontinued midway. A total of 30 gm was administered in case 1 as compared to 80 gm in case 2.

**CONCLUSION**

The combination of ultrasound Doppler PSV-MCA and IVIg would emerge as an ideal option to manage cases with rhesus alloimmunization. The noninvasive nature will be an asset since it can be carried out without any intervention. Such an approach would more than offset the existing rather prohibitive cost of IVIg.
ACKNOWLEDGMENT

We would like to thank Mrs Geeta Rana for her secretarial assistance.

REFERENCES


ABOUT THE AUTHORS

Nirmala Agarwal (Corresponding Author)
Senior Consultant and Head, Department of Obstetrics and Gynecology, Sant Parmanand Hospital, New Delhi, India, Phone: 9811888732, e-mail: n.menoky@gmail.com

Sweta Balani
Consultant, Department of Obstetrics and Gynecology, Sant Parmanand Hospital, New Delhi, India

Subhash Arya
Laboratory Head, Department of Obstetrics and Gynecology Sant Parmanand Hospital, New Delhi, India

Ratna Dua Puri
Senior Consultant, Centre of Medical Genetics, Sir Gangaram Hospital New Delhi, India